

ForPatients

by Roche

Hepatitis B Virus

A Study of RO7239958 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus Infection

Trial Status
Terminated

Trial Runs In
7 Countries

Trial Identifier
NCT03762681 NP40520

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This study is designed to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single and multiple ascending doses in healthy volunteers (HV) and participants diagnosed with chronic hepatitis B (CHB).

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT03762681 NP40520
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>=18 Years & <= 65 Years

Healthy Volunteers
Accepts Healthy Volunteers
